ALFA Finder| Management target | Revenue 2032 |
|---|
| Revenue growth | 13% p.a. revenue growth from FY24 to FY26. |
|---|---|
| Margins | EBITDA margins rising significantly post-merger due to synergies. |
| Demand visibility | Strong; backed by 150+ country presence and patent cliffs. |
| Management confidence | High; aiming for top 10 global animal health player. |
Growth
FY26 revenue reached INR 34,203 Mn (13% CAGR) with EBITDA at INR 7,025 Mn showing significant margin expansion (60% CAGR).
Outlook
2032 Aspiration: ~$1Bn Revenue, ~$250Mn EBITDA, and 25%+ ROCE. Targeting 20%+ growth in CDMO segment.
Risks
Regulatory compliance at 16 facilities and successful integration of the Bio For Life Italy acquisition.
Last quarter's promises, checked
Delivered
- Guided 20% EBITDA margin → delivered 20.5% (= BEAT)
- Targeted INR 50-60Cr merger synergies → delivered ~INR 60Cr annualized (= BEAT)
- Guided animal health API growth → delivered INR 400Cr run rate from INR 350Cr (= BEAT)
Partly delivered
- Guided FY26 Revenue INR 3,500Cr+ → delivered INR 3,420Cr (= PARTIAL)
Earnings Call filed with NSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹255.33
- Market cap
- ₹11,285 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 65.9×Sector 43.8×
- Promoter holding
- 49.24%-12.07% QoQ
- FII holding
- 2.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 228,408 shares under two employee stock option schemes. Paid-up capital rose to 44,19,91,958 shares of Rs.2 each.
Viyash Scientific Board Meeting Date
Viyash Scientific will hold a board meeting on 13 November 2026 to consider unaudited quarterly and half-yearly results. The trading window remains closed until 15 November 2026.
Viyash Scientific Merger & Restructuring Worth ₹3.8 Cr
Viyash's step-down subsidiary Alivira Vietnam was incorporated on 30 October 2026, with investment up to USD 400,000. It will distribute animal health products and APIs in Vietnam.
- Value
- ₹3.80 Cr
Viyash Scientific Management Change
Viyash Scientific Limited has appointed Dr. Mallikharjuna Rao Nagineni as Senior Vice President, Human Resources, succeeding the retiring Mr. Prasad Lad.
Viyash Scientific Capital Structure Change
White Oak Capital Management Consultants LLP disclosed the sale of 8,747,392 equity shares of Viyash Scientific Ltd, reducing its stake in the open market.
Viyash Scientific Other Announcement
Viyash Scientific Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.